New drug aims to free patients from frequent blood transfusions
NCT ID NCT07319845
Summary
This study is testing an investigational drug called TAK-226 to see if it can help Japanese adults with a lower-risk bone marrow disorder become less dependent on regular blood transfusions. The main goal is to see if participants can go at least 8 weeks without needing a transfusion. About 27 people will receive the drug and be followed for safety and effectiveness for up to 6 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.